作者: Timothy J Price , Jeremy D Shapiro , Eva Segelov , Christos S Karapetis , Nick Pavlakis
DOI: 10.1586/EGH.11.103
关键词: Combination chemotherapy 、 Taxane 、 Adenocarcinoma 、 Medicine 、 Palliative Radiation Therapy 、 Internal medicine 、 Anthracycline 、 Cancer 、 Evidence-based medicine 、 Docetaxel 、 Oncology
摘要: The management of advanced gastric cancer has only evolved a little over the last 15 years: platinum and fluoropyrimidine chemotherapy remains backbone therapy with ongoing debate as to benefit triplet either an anthracycline or taxane. Recently published trials biological agents, in particular those targeting Her2 receptor, have provided some signs improvement. This article summarizes relevant literature, discusses role these well geographical variations use, provides recommendations regarding both 'standard chemotherapy' agents cancer. Given relative lack progress for years, focus next 5 years should be on improved understanding molecular basis cancer, thus allowing rational integration new agents.